Research Interests: Clinical and basic mechanisms of hypertension, pulmonary embolism and cardiovascular endocrinology.

Principal Investigator

· Directed over 20 national research projects supported by the Beijing Scientific Association and tasks of the Ministry of Health and Beijing Key Discipline, including “Changes in circulatory and endocrine, vascular endothelial function and blood factors after coronary artery bypass graft surgery”. Support period: 2000–2003; “Research of inflammation and arthrosclerosis”. Support period: 2000–2003; “Basic and clinical research of pulmonary embolism”. Support period: 2001–2003; and “Basic and clinical research of the association between pericardium endocrine function and cardiopathy”. Support period: 2001–2003.

· Directed projects supported by National Natural Science Foundation of China and Beijing Natural Science Foundation, including “Role of Ca2+-Calpain signaling pathway in left ventricular hypertrophy” (7992034). Support period: 2000–2003; and “The influence of HSG on the proliferation of vascular smooth muscle cells in human hypertension” (707308). Support period: 2007–2008.

· “Clinical pharmacotherapy study of hypertension: Whether felodipine can decrease the complications of the cardio-cerebrovascular diseases”. Funded by the National Key Program in Science and Technologies (Key Technology Research and Development Program in the Seventh and Ninth Five-year Plan Period). Support period: 2001–2004.

· “Mechanism of microelement regulating stress reaction”. Funded by the National Research Special Prior to 973 (2003CCA041). Support period: 2003–2005.

· “Study of monitoring perioperative period oxygen metabolism and humoral factors in infants with severe congenital heart disease”. Funded by the Beijing Municipal Science and Technology Commission (Y0204003040931). Support period: 2005–2008.

· “Basic and clinical research of the association between HSG and essential hypertension”. Funded by the National High Technology Research and Development Program (863 Program) (2008AA02Z441). Support period: 2008–2010.

· “Study of establishment of the early warning system and risk assessment for essential hypertension in the Beijing area”. Funded by the Beijing Natural Science Foundation (7120001). Support period: 2012–2015.

SCI papers published in the past five years:

1. Liu Y, Lou YQ, Liu K, Liu JL, Wang ZG, Wen J, Zhao Q, Wen SJ, Xiao L Role of Leptin receptor gene polymorphisms in susceptibility to the development of essential hypertension: a case-control associationstudy in a Northern Han Chinese population. J Hum Hypertens. 2014;28(9):551-6.

2. Lou Y, Li R, Xiong L, Gu A, Shi C, Chu T, Zhang X, Gu P, Zhong H, Wen S, Han B. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2013;34(6):3967-79.

3. Wang Z, Liu Y, Liu J, Niu Q, Wen J, Wen S, Wu Z. A Novel 5'-Uncoding Region -1248 A>G Variation of Mitofusin-2 Gene Is Associated with Hypertension in Chinese. Yonsei Med J. 2013;54(3):603-8

4. Wang Z, Liu Y, Liu J, Liu K, Wen J, Wen S, Wu Z. HSG/Mfn2 gene polymorphism and essential hypertension: a case-control association study in Chinese. J Atheroscler Thromb. 2011;18(1):24-31.

5. Lou Y, Liu J, Li Y, Liu Y, Wang Z, Liu K, Wu H, Niu Q, Gu W, Guo Y, Li Z, Wen S. Association Study of the β2-Adrenergic Receptor Gene Polymorphisms and hypertension in the Northern Han Chinese. PLoS One. 2011;6(4):e18590.

6. Gu W, Liu J, Niu Q, Wang H, Lou Y, Liu K, Wang L, Wang Z, Zhang J, Wen S. A-6G and A-20C polymorphisms in the angiotensinogen promoter and hypertension risk in Chinese: A meta-analysis. PLoS One. 2011;6(12):e29489.

7. Wang Z, Liu Y, Liu J, Liu K, Lou Y, Wen J, Niu Q, Wen S, Wu Z. E-selectin gene polymorphisms are associated with essential hypertension: a case-control pilot study in a Chinese population. BMC Med Genet. 2010;11:127

8. Liu K, Liu J, Huang Y, Liu Y, Lou Y, Wang Z, Zhang H, Yan S, Li Z, Wen S Alpha-adducin Gly460Trp polymorphism and hypertension risk: a meta-analysis of 22 studies including 14303 cases and 15961 controls. PLoS One. 2010;5(9). pii: e13057

Address：E-mail：wenshaojun@aliyun.com Tel：010-64456268